Donepezil typically provides its strongest cognitive benefits during the first 6 to 9 months of treatment, after which its effects gradually shift from active improvement to slowing the rate of decline. That initial window of stabilization or mild improvement doesn’t mean the drug stops working entirely, though. Clinical data shows measurable benefits lasting up to 2 to 3 years, and some patients have continued treatment for nearly 5 years with acceptable tolerability.
The First 6 to 9 Months
The clearest benefits appear early. During the first 6 to 9 months, patients in long-term studies showed genuine improvement on standardized tests of cognition and daily functioning, not just a slowing of decline but actual gains compared to where they started. Scores on widely used cognitive assessments improved or held steady at above-baseline levels during this period.
This early response matters more than you might think. Research shows that patients who gain at least 3 points on the standard Alzheimer’s cognitive scale in the first months of treatment are nearly 7 times more likely to still be showing benefit at the end of the study period. Conversely, patients who deteriorate early on are unlikely to see later improvement, which gives doctors a useful signal for whether the medication is worth continuing.
Benefits From Year One Through Year Three
After that initial improvement phase, donepezil doesn’t suddenly stop helping. A large randomized trial published in The Lancet, following 565 patients, found that cognition averaged about 0.8 points better on the Mini-Mental State Examination and daily functioning averaged 1.0 point better on a functional scale in patients taking donepezil compared to placebo over the first 2 years. Those are modest differences on paper, but in practical terms they can mean the difference between someone managing a daily routine independently and needing help.
What changes after the first several months is the nature of the benefit. Rather than improving cognition, the drug shifts to slowing the decline that Alzheimer’s would otherwise cause. Patients still lose function over time because donepezil treats symptoms without altering the underlying disease progression. But they lose it more slowly than they would without the medication.
Starting Earlier Makes a Difference
When donepezil is started matters significantly. Patients with mild Alzheimer’s (generally those who still score 21 or above on the 30-point Mini-Mental State Examination) get more out of the drug than those who start in the moderate stage. One study found that patients treated with donepezil from the time of diagnosis had significantly better cognitive outcomes up to 3 years later than patients whose treatment was delayed by just one year.
This isn’t surprising when you consider how the drug works. Donepezil increases levels of a chemical messenger in the brain that supports memory, attention, and the ability to carry out everyday tasks. In earlier disease stages, more of the brain cells that rely on this messenger are still intact, so there’s more circuitry for the drug to support. As Alzheimer’s destroys more of those cells over time, donepezil has less to work with.
Higher Doses in Later Stages
Most patients start on a lower dose and move to 10 mg daily after several weeks. For people with moderate to severe Alzheimer’s who seem to be losing the benefit of the standard dose, a higher 23 mg dose is available. In a 24-week trial of nearly 1,500 patients, the higher dose produced significantly greater improvement on a cognitive test designed for more advanced dementia compared to the 10 mg dose.
The benefit was most pronounced in patients with more advanced disease. Those with greater impairment at the start showed a meaningful cognitive advantage on the higher dose, while less impaired patients saw a smaller difference between the two doses. The trade-off is that higher doses come with more side effects, particularly nausea and vomiting, so the decision involves weighing cognitive benefit against tolerability.
What Happens if You Stop Taking It
One of the most important things to understand about donepezil’s effectiveness is what happens when it’s discontinued. Stopping the medication, even after years of use, typically leads to a noticeable cognitive drop. Patients who discontinue don’t simply return to where they would have been without treatment. They often experience a relatively rapid decline that can be distressing for both the person and their family.
This is part of why doctors are often reluctant to stop donepezil even when its benefits seem subtle. The drug may be doing more than what’s visible on the surface. A patient who appears to be declining despite treatment may still be declining more slowly than they would without it, and that gap only becomes apparent when the medication is removed.
Realistic Expectations Over Time
The honest answer to how long donepezil is effective is that it depends on what you mean by “effective.” If you define it as noticeable cognitive improvement, the window is roughly 6 to 9 months for most patients. If you define it as performing better than you would without the drug, the evidence supports benefits lasting 2 to 3 years, and some patients have been treated for close to 5 years in clinical studies.
What donepezil cannot do is stop Alzheimer’s from progressing. It buys time and preserves function during a critical period when independence and quality of life are at stake. For many families, the months or years of maintained ability to recognize loved ones, follow conversations, or handle basic self-care tasks represent the drug’s most meaningful contribution, even if the numbers on a cognitive test eventually trend downward.